Cadrenal Therapeutics, Inc. (CVKD) Stock

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. is led by CEO Quang X. Pham, employs 4 people, headquartered in US, publicly traded since 2023.

Cadrenal Therapeutics, Inc. (CVKD) stock trades at $0.96 with a market capitalization of $3.42M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.19, reflecting a net loss over the last twelve months, price-to-book of 0.67, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.83 and $14.50, and currently trades 93.4% below its 52-week high.

On profitability, Cadrenal Therapeutics, Inc. generates a return on equity (ROE) of -406.38% (negative, reflecting a net loss), return on capital employed of -284.81%.

Cadrenal Therapeutics, Inc. by the numbers, 2022–2025

Between 2022 and 2025 Cadrenal Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-13.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-11.0M.

Borrowings fell from $1.0M to $0, cash from operations was $-13.0M in the latest year, positive in 0 of the last 4.

Return on equity has averaged -143.4% over five years, and was -433.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Cadrenal Therapeutics, Inc. (CVKD) — frequently asked questions